Investor Relations

Overview Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The Company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.   View Cerus' 2007 Annual Report   View Cerus' Safe-Harbor Statement Upcoming Events There are currently no events scheduled. Recent News 08/12/08 Cerus' INTERCEPT Blood System Receives CE Mark Label Expansion for Treatment of Previously Frozen Plasma 07/31/08 Cerus Corporation Announces Second Quarter Financial Results 07/23/08 Cerus Expands INTERCEPT Distribution Network

Investor Relations Contact William J. Dawson VP, Finance & Chief Financial Officer Phone: 925-288-6053 Fax: 925.288.0194 E-mail: ir@cerus.com Stock Quote CERS (Common Stock) Exchange NASDAQ GM Price $4.52 Change (%)   0.07 (1.53%) Volume 59,100 Intraday High $4.83 Intraday Low $4.49 Data as of 08/20/08 4:00 p.m. ET Minimum 20 minute delay Receive Email Alerts Alerts are emailed to you whenever certain new company information is posted to this site. Sign-up Now!